TY - JOUR
T1 - APOE and the association of fatty acids with the risk of stroke, coronary heart disease, and mortality
AU - Satizabal, Claudia L.
AU - Samieri, Cécilia
AU - Davis-Plourde, Kendra L.
AU - Voetsch, Barbara
AU - Aparicio, Hugo J.
AU - Pase, Matthew P.
AU - Romero, José Rafael
AU - Helmer, Catherine
AU - Vasan, Ramachandran S.
AU - Kase, Carlos S.
AU - Debette, Stéphanie
AU - Beiser, Alexa S.
AU - Seshadri, Sudha
N1 - Funding Information:
This work was supported by the National Heart, Lung and Blood Institute (Framingham Heart Study contract No. N01-HC-25195 and HHSN268201500001I), the Boston University School of Medicine, and by grants from the National Institute on Aging (AG054076, AG008122, and AG033193) and the National Institute of Neurological Disorders and Stroke (NS017950 and NS100605). Dr Pase is funded by an Australian National Health and Medical Research Council Early Career Fellowship (APP1089698). The 3C Study (Three-City) is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut de Santé Publique et Développement of the Victor Segalen Bordeaux-2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l'Education Nationale, Institut de la Longévité, Regional Governments of Aquitaine and Bourgogne, Fondation de France, Ministry of Research-INSERM Programme Cohortes et collections de données biologiques, French National Research Agency COGINUT (Cognition, Anti-Oxydants, Acides Gras: Approche Interdisciplinaire de le Nutrition dans le Vieillissement Cérébral) ANR-06-PNRA-005, the Fondation Plan Alzheimer (FCS 2009- 2012), and the Caisse Nationale pour la Solidarité et l'Autonomie.
Funding Information:
This work was supported by the National Heart, Lung and Blood Institute (Framingham Heart Study contract No. N01-HC-25195 and HHSN268201500001I), the Boston University School of Medicine, and by grants from the National Institute on Aging (AG054076, AG008122, and AG033193) and the National Institute of Neurological Disorders and Stroke (NS017950 and NS100605). Dr Pase is funded by an Australian National Health and Medical Research Council Early Career Fellowship (APP1089698). The 3C Study (Three-City) is conducted under a partnership agreement between the Institut National de la Santé et de la Recherche Médicale (INSERM), the Institut de Santé Publique et Développement of the Victor Segalen Bordeaux-2 University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale, Institut de la Longévité, Regional Governments of Aquitaine and Bourgogne, Fondation de France, Ministry of Research-INSERM Programme Cohortes et collections de données biologiques, French National Research Agency COGINUT (Cognition, Anti-Oxydants, Acides Gras: Approche Interdisciplinaire de le Nutrition dans le Vieillissement Cérébral) ANR-06-PNRA-005, the Fondation Plan Alzheimer (FCS 2009– 2012), and the Caisse Nationale pour la Solidarité et l’Autonomie.
Publisher Copyright:
© 2018 American Heart Association, Inc.
PY - 2018
Y1 - 2018
N2 - Background and Purpose-The role of dietary fat on cardiovascular health and mortality remains under debate. Because the APOE is central to the transport and metabolism of lipids, we examined associations between plasma fatty acids and the risk of stroke, coronary heart disease, and mortality by APOE-ϵ4 genotype. Methods-We included 943 FHS (Framingham Heart Study) and 1406 3C (Three-City) Bordeaux Study participants. Plasma docosahexaenoic, linoleic, arachidonic, and palmitic fatty acids were measured at baseline by gas chromatography. Allcause stroke, ischemic stroke, coronary heart disease, and all-cause mortality events were identified prospectively using standardized protocols. Each cohort used Cox models to separately relate fatty acid levels to the risk of developing each event during ≤10 years of follow-up adjusting for potential confounders and stratifying by APOE genotype (ϵ4 carriers versus noncarriers). We then meta-analyzed summary statistics using random-effects models. Results-On average, participants had a mean age of 74 years, 61% were women, and 21% (n=483) were APOE-ϵ4 carriers. Meta-analysis results showed that, only among APOE-ϵ4 carriers, every SD unit increase in linoleic acid was associated with a reduced risk of all-cause stroke (hazard ratio [HR], 0.54 [95% CI, 0.38.0.78]), ischemic stroke (HR, 0.48 [95% CI, 0.33.0.71]), and all-cause mortality (HR, 0.70 [95% CI, 0.57.0.85]). In contrast, every SD unit increase in palmitic acid was related to an increased risk of all-cause stroke (HR, 1.58 [95% CI, 1.16.2.17]), ischemic stroke (HR, 1.76 [95% CI, 1.26.2.45]), and coronary heart disease (HR, 1.48 [95% CI, 1.09.2.01]), also in APOE-ϵ4 carriers only. Results for docosahexaenoic acid and arachidonic acid were heterogeneous between cohorts. Conclusions-These exploratory results suggest that APOE-ϵ4 carriers may be more susceptible to the beneficial or adverse impact of fatty acids on cardiovascular disease and mortality. In this subgroup, higher linoleic acid was protective for stroke and mortality, whereas palmitic acid was a risk factor for stroke and coronary heart disease. The mechanisms underlying these novel findings warrant further investigation.
AB - Background and Purpose-The role of dietary fat on cardiovascular health and mortality remains under debate. Because the APOE is central to the transport and metabolism of lipids, we examined associations between plasma fatty acids and the risk of stroke, coronary heart disease, and mortality by APOE-ϵ4 genotype. Methods-We included 943 FHS (Framingham Heart Study) and 1406 3C (Three-City) Bordeaux Study participants. Plasma docosahexaenoic, linoleic, arachidonic, and palmitic fatty acids were measured at baseline by gas chromatography. Allcause stroke, ischemic stroke, coronary heart disease, and all-cause mortality events were identified prospectively using standardized protocols. Each cohort used Cox models to separately relate fatty acid levels to the risk of developing each event during ≤10 years of follow-up adjusting for potential confounders and stratifying by APOE genotype (ϵ4 carriers versus noncarriers). We then meta-analyzed summary statistics using random-effects models. Results-On average, participants had a mean age of 74 years, 61% were women, and 21% (n=483) were APOE-ϵ4 carriers. Meta-analysis results showed that, only among APOE-ϵ4 carriers, every SD unit increase in linoleic acid was associated with a reduced risk of all-cause stroke (hazard ratio [HR], 0.54 [95% CI, 0.38.0.78]), ischemic stroke (HR, 0.48 [95% CI, 0.33.0.71]), and all-cause mortality (HR, 0.70 [95% CI, 0.57.0.85]). In contrast, every SD unit increase in palmitic acid was related to an increased risk of all-cause stroke (HR, 1.58 [95% CI, 1.16.2.17]), ischemic stroke (HR, 1.76 [95% CI, 1.26.2.45]), and coronary heart disease (HR, 1.48 [95% CI, 1.09.2.01]), also in APOE-ϵ4 carriers only. Results for docosahexaenoic acid and arachidonic acid were heterogeneous between cohorts. Conclusions-These exploratory results suggest that APOE-ϵ4 carriers may be more susceptible to the beneficial or adverse impact of fatty acids on cardiovascular disease and mortality. In this subgroup, higher linoleic acid was protective for stroke and mortality, whereas palmitic acid was a risk factor for stroke and coronary heart disease. The mechanisms underlying these novel findings warrant further investigation.
KW - Apolipoproteins E
KW - Cardiovascular diseases
KW - Humans
KW - Lipids
KW - Mortality
UR - http://www.scopus.com/inward/record.url?scp=85058907026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058907026&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.118.022132
DO - 10.1161/STROKEAHA.118.022132
M3 - Article
C2 - 30571417
AN - SCOPUS:85058907026
SN - 0039-2499
VL - 49
SP - 2822
EP - 2829
JO - Stroke
JF - Stroke
IS - 12
ER -